FDA Signals Aging as Priority for Future Regulatory Science
At ARDD 2026, senior FDA officials confirmed that aging and longevity will be included in the agency's upcoming focus areas of regulatory science. The panel outlined a phased approach to approving anti-aging therapies, starting with hard endpoints like mortality and comorbidity prevention before moving to validated surrogate measures. They emphasized the need for pre-competitive consortia to develop shared biomarkers and warned against repurposing existing drugs without clear evidence of broader benefits.